Chugai Pharmaceutical Co., Ltd. (4519.T) stock analysis

In our weekly check, Chugai Pharmaceutical Co., Ltd. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2.

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. is a Healthcare company (Drug Manufacturers - General) based in Japan, listed on JPX as 4519.T.

What our checks show for 4519.T

Red flags

• The stock has fallen as much as 66% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 6.1 years.

Warning signs

• Revenue grew only 2.1% a year over the last 3 years.
• The dividend takes 95% of profit: little cushion if profit falls.
• The price swings a lot: 41.2% annual volatility. Expect large ups and downs.

Strengths

• Debt is low: 0.01x equity.
• Operating profit covers interest 653 times over.
• The net margin rose by 4.8 points over 5 years, to 35.1%.
• The gross margin is 71.4% and has risen by 5.3 points: pricing power is holding.
• Analysts expect earnings per share to grow about 14% a year over the next years.
• Analysts expect the net margin to improve by 5.8 points from today's 35.1%.

Next earnings report: 2026-10-27

Similar companies

4578.T · 4568.T · 4503.T · LLY

Questions

What grade does Chugai Pharmaceutical Co., Ltd. (4519.T) have?

In our weekly check, Chugai Pharmaceutical Co., Ltd. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 4519.T stock?

This week's biggest flags for Chugai Pharmaceutical Co., Ltd.: Deep past fall, Slow recovery after falls, Weak revenue growth. In total 5 of 25 checks show a warning or a red flag.

What does Chugai Pharmaceutical Co., Ltd. do?

Chugai Pharmaceutical Co., Ltd. is a Healthcare company (Drug Manufacturers - General) based in Japan, listed on JPX as 4519.T.

When does Chugai Pharmaceutical Co., Ltd. report earnings next?

The next earnings report is expected on 2026-10-27. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis